An update on peritoneal dialysis solutions (Q37986357)

26 August 2017

An update on peritoneal dialysis solutions (English)

1 reference

26 August 2017

0 references

1 reference

2

Bengt Lindholm

1 reference

26 August 2017

Elvia García-López

1

1 reference

PubMed ID

22349485

26 August 2017

Simon Davies

series ordinal

3

1 reference

PubMed ID

22349485

26 August 2017

language of work or name

English

0 references

publication date

21 February 2012

1 reference

Nature Reviews Nephrology

26 August 2017

1 reference

26 August 2017

8

1 reference

26 August 2017

224-233

1 reference

26 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2012.13

26 August 2017

0 references

cites work

Biocompatibility of peritoneal dialysis fluid and influence of compositions on peritoneal fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Update on peritoneal dialysis solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Glucose degradation products (GDP) retard remesothelialization independently of d-glucose concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: benefit at bench, bedside, or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Changes in peritoneal mesothelial cells phenotype after chronic exposure to glucose or N-acetylglucosamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

3,4-di-deoxyglucosone-3-ene promotes leukocyte apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

High glucose-induced PKC activation mediates TGF-beta 1 and fibronectin synthesis by peritoneal mesothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Glucose degradation products downregulate ZO-1 expression in human peritoneal mesothelial cells: the role of VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Low-GDP peritoneal dialysis fluid ('balance') has less impact in vitro and ex vivo on epithelial-to-mesenchymal transition (EMT) of mesothelial cells than a standard fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Improved Acidosis Correction and Recovery of Mesothelial Cell Mass with Neutral-pH Bicarbonate Dialysis Solution among Children Undergoing Automated Peritoneal Dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Impact of systemic and local peritoneal inflammation on peritoneal solute transport rate in new peritoneal dialysis patients: a 1-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Intra-peritoneal interleukin-6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Effect of fluid and sodium removal on mortality in peritoneal dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Survival of functionally anuric patients on automated peritoneal dialysis: the European APD Outcome Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Cardiovascular risk in the peritoneal dialysis patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Dry body weight: water and sodium removal targets in PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Randomized controlled trial of icodextrin versus glucose containing peritoneal dialysis fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Influence of convection on the diffusive transport and sieving of water and small solutes across the peritoneal membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Role of advanced glycation end products in diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Obesity is associated with worse peritoneal dialysis outcomes in the Australia and New Zealand patient populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Body mass index, dialysis modality, and survival: analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Visceral fat, arterial stiffness, and endothelial function in peritoneal dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Reducing cardiometabolic risk in peritoneal dialysis patients: role of the dialysis solution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Glucose-containing peritoneal dialysis fluids regulate leptin secretion from 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Effects of icodextrin on insulin resistance and adipocytokine profiles in patients on peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Dialysate as food: combined amino acid and glucose dialysate improves protein anabolism in renal failure patients on automated peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Cardiovascular and noncardiovascular mortality among patients starting dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Mononuclear leucocyte function tests in the assessment of the biocompatibility of peritoneal dialysis fluids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Osmotic agents and buffers in peritoneal dialysis solution: monocyte cytokine release and in vitro cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Icodextrin does not impact infectious and culture-negative peritonitis rates in peritoneal dialysis patients: a 2-year multicentre, comparative, prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Icodextrin provides long dwell peritoneal dialysis and maintenance of intraperitoneal volume

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Comparison of infectious complications between incident hemodialysis and peritoneal dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Propensity-matched mortality comparison of incident hemodialysis and peritoneal dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Biocompatible peritoneal dialysis solutions: do we have one?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Longitudinal relationships between fluid status, inflammation, urine volume and plasma metabolites of icodextrin in patients randomized to glucose or icodextrin for the long exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

A 3-year, prospective, randomized, controlled study on amino acid dialysate in patients on CAPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Mortality and technique failure in peritoneal dialysis patients using advanced peritoneal dialysis solutions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Short-term effects of bicarbonate/lactate-buffered and conventional lactate-buffered dialysis solutions on peritoneal ultrafiltration: a comparative crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

L-carnitine: more than just an alternative to glucose as an osmotic agent for peritoneal dialysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

The effects of low-sodium peritoneal dialysis fluids on blood pressure, thirst and volume status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

The effects of a dialysis solution with a combination of glycerol/amino acids/dextrose on the peritoneal membrane in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Daily peritoneal administration of sodium pyrophosphate in a dialysis solution prevents the development of vascular calcification in a mouse model of uraemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Membrane longevity in peritoneal dialysis: impact of infection and bio-incompatible solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

In vitro biocompatibility performance of Physioneal.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Peritoneal transport characteristics with glucose polymer based dialysate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Long-term use of 1.1% amino acid dialysis solution in hypoalbuminemic continuous ambulatory peritoneal dialysis patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: results of a multicenter outpatient study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Morphological and morphometric changes in mesothelial cells during peritoneal dialysis in the rabbit

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Oxidative stress during peritoneal dialysis: implications in functional and structural changes in the membrane

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Early diagnostic markers for encapsulating peritoneal sclerosis: a case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Growth factors VEGF and TGF-beta1 in peritoneal dialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Comparison of icodextrin and glucose solutions for the daytime dwell in automated peritoneal dialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Glucose oxidation after a peritoneal and an oral glucose load in dialyzed patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Effects of icodextrin on glycemic and lipid profiles in diabetic patients undergoing peritoneal dialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Changes in fat mass after initiation of maintenance dialysis is influenced by the uncoupling protein 2 exon 8 insertion/deletion polymorphism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

31 March 2020

12 December 2020

Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Impact of new dialysis solutions on peritonitis rates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Echocardiographic, electrocardiographic and blood pressure changes induced by icodextrin solution in diabetic patients on peritoneal dialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Effects of icodextrin on patient survival and technique success in patients undergoing peritoneal dialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

L-carnitine is an osmotic agent suitable for peritoneal dialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.13

Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Dialysis

31 March 2020

1 reference

12 December 2020

Effect of glucose degradation products on human peritoneal mesothelial cell function

1 reference

12 December 2020

Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis

1 reference

12 December 2020

Icodextrin preserves residual renal function in patients treated with automated peritoneal dialysis

1 reference

12 December 2020

Serum advanced glycosylation end-products in patients on hemodialysis and CAPD

1 reference

12 December 2020

Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance).

1 reference

12 December 2020

Long-term clinical experience with pure bicarbonate peritoneal dialysis solutions

1 reference

12 December 2020

Analysis of the prevalence and causes of ultrafiltration failure during long-term peritoneal dialysis: a cross-sectional study.

1 reference

12 December 2020

Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane.

1 reference

12 December 2020

Large body mass index does not predict short-term survival in peritoneal dialysis patients.

1 reference

12 December 2020

High glucose solution and spent dialysate stimulate the synthesis of transforming growth factor-beta1 of human peritoneal mesothelial cells: effect of cytokine costimulation

1 reference

12 December 2020

Better preservation of peritoneal morphologic features and defense in rats after long-term exposure to a bicarbonate/lactate-buffered solution.

1 reference

12 December 2020

Novel low Na peritoneal dialysis solutions designed to optimize Na gap of effluent: kinetics of Na and water removal

1 reference

12 December 2020

Analytical interferences in point-of-care testing glucometers by icodextrin and its metabolites: an overview.

1 reference

12 December 2020

Vascular and other tissue calcification in peritoneal dialysis patients

1 reference

12 December 2020

Single exposure of mesothelial cells to glucose degradation products (GDPs) yields early advanced glycation end-products (AGEs) and a proinflammatory response.

1 reference

12 December 2020

Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group.

1 reference

12 December 2020

Peritoneal defense using icodextrin or glucose for daytime dwell in CCPD patients

1 reference

12 December 2020

Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: extension of CAPD technique survival

1 reference

12 December 2020

European best practice guidelines for peritoneal dialysis. 5 Peritoneal dialysis solutions

1 reference

12 December 2020

Lactate-buffered and bicarbonate-buffered solutions with less glucose degradation products in a two-chamber system

1 reference

12 December 2020

Effects of conventional and new peritoneal dialysis solutions on human peritoneal mesothelial cell viability and proliferation

1 reference

12 December 2020

Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane?

1 reference

12 December 2020

Biocompatibility of a peritoneal dialysis solution with amino acids: histological evaluation in the rabbit

1 reference

12 December 2020

Determinants of peritoneal solute transport rates in newly started nondiabetic peritoneal dialysis patients.

1 reference

12 December 2020

Risk factors responsible for ultrafiltration failure in early stages of peritoneal dialysis

1 reference

12 December 2020

Icodextrin reduces mortality and the drop-out rate in Japanese peritoneal dialysis patients.

1 reference

12 December 2020

Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients.

1 reference

12 December 2020

Short-term effects of a new bicarbonate/lactate-buffered and conventional peritoneal dialysis fluid on peritoneal and systemic inflammation in CAPD patients: a randomized controlled study.

1 reference

12 December 2020

Better preservation of the peritoneum in rats exposed to amino acid-based peritoneal dialysis fluid.

1 reference

12 December 2020

Glucose dialysate induces mitochondrial DNA damage in peritoneal mesothelial cells.

1 reference

12 December 2020

Use of icodextrin during nocturnal automated peritoneal dialysis allows sustained ultrafiltration while reducing the peritoneal glucose load: a randomized crossover study

1 reference

12 December 2020

Effects of different peritoneal dialysis fluids on the TH1/TH2 balance.

1 reference

12 December 2020

Icodextrin effluent leads to a greater proliferation than glucose effluent of human mesothelial cells studied ex vivo

1 reference

12 December 2020

Endotoxin-induced chemokine expression in murine peritoneal mesothelial cells: the role of toll-like receptor 4.

1 reference

12 December 2020

Effects of peritoneal dialysis solutions low in GDPs on peritonitis and exit-site infection rates.

1 reference

12 December 2020

Amadori albumin and advanced glycation end-product formation in peritoneal dialysis using icodextrin

1 reference

12 December 2020

Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients

1 reference

12 December 2020

Icodextrin metabolites in peritoneal dialysis

1 reference

12 December 2020

Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells.

1 reference

12 December 2020

The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial

1 reference

12 December 2020

Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions

1 reference

12 December 2020

Effect of icodextrin-based peritoneal dialysis solution on peritoneal membrane

1 reference

12 December 2020

Acceleration of neutrophil apoptosis by glucose-containing peritoneal dialysis solutions: role of caspases

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2012.13

1 reference

26 August 2017

1 reference

PubMed ID

22349485